Skip to main content
Erschienen in: Endocrine 2/2014

01.06.2014 | Original Article

Glycemic variability in normal glucose regulation subjects with elevated 1-h postload plasma glucose levels

verfasst von: Jian-bin Su, Tong Chen, Feng Xu, Xue-qin Wang, Jin-feng Chen, Gang Wu, Yan Jin, Xiao-hua Wang

Erschienen in: Endocrine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Subjects with normal glucose regulation (NGR), whose 1-h postload plasma glucose is ≥8.6 mmol/L (155 mg/dL, NGR 1 h ≥ 8.6) during 75-g oral glucose tolerance test (OGTT), have an increased risk of type 2 diabetes and subclinical organ damage. And, the deficiency in islet β cell function is responsible for glycemic disorders. The purpose of this study is to investigate glycemic variability in NGR subjects with elevated 1-h postload plasma glucose levels and its association with islet β cell function. The 29 NGR subjects with 1-h postload plasma glucose ≥8.6 mmol/L (NGR 1 h ≥ 8.6) and 29 age- and sex-matched NGR subjects with 1-h postload plasma glucose <8.6 mmol/L (NGR 1 h < 8.6) were recruited in the study. Insulin sensitivity (Matsuda index, ISI), insulin secretion (insulinogenic index ΔI30/ΔG30), and integrated β cell function measured by the oral disposition index (ΔI30/ΔG30 multiplied by the ISI) were derived from OGTT. All subjects were monitored using the continuous glucose monitoring system for consecutive 72 h. The multiple parameters of glycemic variability included the standard deviation of blood glucose (SDBG), mean blood glucose (MBG), mean of daily differences (MODD), and mean amplitude of glycemic excursions (MAGE). MAGE is considered as a gold standard of glycemic variability. Glycemic variability parameters SDBG, MBG, MODD, and MAGE in NGR 1 h ≥ 8.6 group were higher than those in NGR 1 h < 8.6 group (p < 0.05), and oral disposition index in NGR 1 h ≥ 8.6 group was lower than that in NGR 1 h < 8.6 group (p < 0.05). SDBG, MBG, MODD, MAGE, and 1-h postload plasma glucose all negatively associated with oral disposition index in the separate group (p < 0.05) and in the whole subjects (p < 0.05). After multivariate regression analysis, oral disposition index was the strongest independent contributor to MAGE and 1-h postload plasma glucose in the separate group (p < 0.05) and in the whole subjects (p < 0.05). It is concluded that NGR 1 h ≥ 8.6 group had higher glycemic variability and lower oral disposition index, compared with NGR 1 h < 8.6 group. Increased glycemic variability parameters and elevated 1-h postload plasma glucose consistently associated with declined oral disposition index in subjects from NGR 1 h < 8.6 to NGR 1 h ≥ 8.6 group.
Literatur
1.
2.
Zurück zum Zitat M.A. Abdul-Ghani, T. Abdul-Ghani, N. Ali, R.A. Defronzo, One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31, 1650–1655 (2008)PubMedCentralPubMedCrossRef M.A. Abdul-Ghani, T. Abdul-Ghani, N. Ali, R.A. Defronzo, One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31, 1650–1655 (2008)PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat E. Succurro, M.A. Marini, F. Arturi, A. Grembiale, M. Lugarà, F. Andreozzi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 207, 245–249 (2009)PubMedCrossRef E. Succurro, M.A. Marini, F. Arturi, A. Grembiale, M. Lugarà, F. Andreozzi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 207, 245–249 (2009)PubMedCrossRef
4.
Zurück zum Zitat E. Succurro, F. Arturi, M. Lugarà, A. Grembiale, T.V. Fiorentino, V. Caruso, F. Andreozzi, A. Sciacqua, M.L. Hribal, F. Perticone, G. Sesti, One-hour postload plasma glucose levels are associated with kidney dysfunction. Clin. J. Am. Soc. Nephrol. 5, 1922–1927 (2010)PubMedCentralPubMedCrossRef E. Succurro, F. Arturi, M. Lugarà, A. Grembiale, T.V. Fiorentino, V. Caruso, F. Andreozzi, A. Sciacqua, M.L. Hribal, F. Perticone, G. Sesti, One-hour postload plasma glucose levels are associated with kidney dysfunction. Clin. J. Am. Soc. Nephrol. 5, 1922–1927 (2010)PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat F. Zaccardi, D. Pitocco, G. Ghirlanda, Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab. Res. Rev. 25, 199–207 (2009)PubMedCrossRef F. Zaccardi, D. Pitocco, G. Ghirlanda, Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab. Res. Rev. 25, 199–207 (2009)PubMedCrossRef
6.
Zurück zum Zitat M. Brownlee, I.B. Hirsch, Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295, 1707–1708 (2006)PubMedCrossRef M. Brownlee, I.B. Hirsch, Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295, 1707–1708 (2006)PubMedCrossRef
7.
Zurück zum Zitat D.C. Klonoff, B. Buckingham, J.S. Christiansen, V.M. Montori, W.V. Tamborlane, R.A. Vigersky, H. Wolpert, Endocrine society, continuous glucose monitoring: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 2968–2979 (2011)PubMedCrossRef D.C. Klonoff, B. Buckingham, J.S. Christiansen, V.M. Montori, W.V. Tamborlane, R.A. Vigersky, H. Wolpert, Endocrine society, continuous glucose monitoring: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 2968–2979 (2011)PubMedCrossRef
8.
Zurück zum Zitat N. Mauras, L. Fox, K. Englert, R.W. Beck, Continuous glucose monitoring in type 1 diabetes. Endocrine 43, 41–50 (2013)PubMedCrossRef N. Mauras, L. Fox, K. Englert, R.W. Beck, Continuous glucose monitoring in type 1 diabetes. Endocrine 43, 41–50 (2013)PubMedCrossRef
9.
Zurück zum Zitat N.R. Hill, N.S. Oliver, P. Choudhary, J.C. Levy, P. Hindmarsh, D.R. Matthews, Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol. Ther. 13, 921–928 (2011)PubMedCentralPubMedCrossRef N.R. Hill, N.S. Oliver, P. Choudhary, J.C. Levy, P. Hindmarsh, D.R. Matthews, Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol. Ther. 13, 921–928 (2011)PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat M.A. Abdul-Ghani, K. Williams, R. DeFronzo, M. Stern, Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 29, 1613–1618 (2006)PubMedCrossRef M.A. Abdul-Ghani, K. Williams, R. DeFronzo, M. Stern, Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care 29, 1613–1618 (2006)PubMedCrossRef
11.
Zurück zum Zitat M.A. Abdul-Ghani, D. Tripathy, R.A. DeFronzo, Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29, 1130–1139 (2006)PubMedCrossRef M.A. Abdul-Ghani, D. Tripathy, R.A. DeFronzo, Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29, 1130–1139 (2006)PubMedCrossRef
12.
Zurück zum Zitat A. Festa, K. Williams, A.J. Hanley, S.M. Haffner, Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57, 1638–1644 (2008)PubMedCrossRef A. Festa, K. Williams, A.J. Hanley, S.M. Haffner, Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57, 1638–1644 (2008)PubMedCrossRef
13.
Zurück zum Zitat M.A. Abdul-Ghani, K. Williams, R.A. DeFronzo, M. Stern, What is the best predictor of future type 2 diabetes? Diabetes Care 30, 1544–1548 (2007)PubMedCrossRef M.A. Abdul-Ghani, K. Williams, R.A. DeFronzo, M. Stern, What is the best predictor of future type 2 diabetes? Diabetes Care 30, 1544–1548 (2007)PubMedCrossRef
14.
Zurück zum Zitat M. Stumvoll, A. Mitrakou, W. Pimenta, T. Jenssen, H. Yki-Järvinen, T. Van Haeften, W. Renn, J. Gerich, Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23, 295–301 (2000)PubMedCrossRef M. Stumvoll, A. Mitrakou, W. Pimenta, T. Jenssen, H. Yki-Järvinen, T. Van Haeften, W. Renn, J. Gerich, Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23, 295–301 (2000)PubMedCrossRef
15.
Zurück zum Zitat J.Y. Kim, D.K. Coletta, L.J. Mandarino, G.Q. Shaibi, Glucose response curve and type 2 diabetes risk in Latino adolescents. Diabetes Care 35, 1925–1930 (2012)PubMedCentralPubMedCrossRef J.Y. Kim, D.K. Coletta, L.J. Mandarino, G.Q. Shaibi, Glucose response curve and type 2 diabetes risk in Latino adolescents. Diabetes Care 35, 1925–1930 (2012)PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)PubMedCrossRef M. Matsuda, R.A. DeFronzo, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999)PubMedCrossRef
17.
Zurück zum Zitat R. Oka, K. Yagi, M. Sakurai, K. Nakamura, T. Moriuchi, S. Miyamoto, A. Nohara, M.A. Kawashiri, Y. Takeda, M. Yamagishi, Insulin secretion and insulin sensitivity on the oral glucose tolerance test (OGTT) in middle-aged Japanese. Endocr. J. 59, 55–64 (2012)PubMedCrossRef R. Oka, K. Yagi, M. Sakurai, K. Nakamura, T. Moriuchi, S. Miyamoto, A. Nohara, M.A. Kawashiri, Y. Takeda, M. Yamagishi, Insulin secretion and insulin sensitivity on the oral glucose tolerance test (OGTT) in middle-aged Japanese. Endocr. J. 59, 55–64 (2012)PubMedCrossRef
18.
Zurück zum Zitat J. Zhou, W. Jia, Y. Bao, X. Ma, W. Lu, H. Li, C. Hu, K. Xiang, Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med. Sci. Monit. 14, CR552–CR558 (2008)PubMed J. Zhou, W. Jia, Y. Bao, X. Ma, W. Lu, H. Li, C. Hu, K. Xiang, Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med. Sci. Monit. 14, CR552–CR558 (2008)PubMed
19.
Zurück zum Zitat J. Zhou, H. Li, X. Ran, W. Yang, Q. Li, Y. Peng, Y. Li, X. Gao, X. Luan, W. Wang, W. Jia, Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med. Sci. Monit. 17, CR9–CR13 (2011)PubMedCentralPubMed J. Zhou, H. Li, X. Ran, W. Yang, Q. Li, Y. Peng, Y. Li, X. Gao, X. Luan, W. Wang, W. Jia, Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med. Sci. Monit. 17, CR9–CR13 (2011)PubMedCentralPubMed
20.
Zurück zum Zitat L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.P. Cristol, C. Colette, Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295, 1681–1687 (2006)PubMedCrossRef L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.P. Cristol, C. Colette, Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295, 1681–1687 (2006)PubMedCrossRef
21.
Zurück zum Zitat K.M. Utzschneider, R.L. Prigeon, M.V. Faulenbach, J. Tong, D.B. Carr, E.J. Boyko, D.L. Leonetti, M.J. McNeely, W.Y. Fujimoto, S.E. Kahn, Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32, 335–341 (2009)PubMedCentralPubMedCrossRef K.M. Utzschneider, R.L. Prigeon, M.V. Faulenbach, J. Tong, D.B. Carr, E.J. Boyko, D.L. Leonetti, M.J. McNeely, W.Y. Fujimoto, S.E. Kahn, Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32, 335–341 (2009)PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat R. Retnakaran, S. Shen, A.J. Hanley, V. Vuksan, J.K. Hamilton, B. Zinman, Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 16, 1901–1907 (2008)CrossRef R. Retnakaran, S. Shen, A.J. Hanley, V. Vuksan, J.K. Hamilton, B. Zinman, Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity (Silver Spring) 16, 1901–1907 (2008)CrossRef
23.
Zurück zum Zitat L. Monnier, C. Colette, D.R. Owens, Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J. Diabetes Sci. Technol. 2, 1094–1100 (2008)PubMedCentralPubMedCrossRef L. Monnier, C. Colette, D.R. Owens, Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J. Diabetes Sci. Technol. 2, 1094–1100 (2008)PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat D. Rodbard, New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol. Ther. 11, 551–565 (2009)PubMedCrossRef D. Rodbard, New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol. Ther. 11, 551–565 (2009)PubMedCrossRef
25.
Zurück zum Zitat F. Moreau, M.A. Weiller, V. Rosner, L. Weiss, M. Hasselmann, M. Pinget, R. Kessler, L. Kessler, Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Horm. Metab. Res. 40, 502–506 (2008)PubMedCrossRef F. Moreau, M.A. Weiller, V. Rosner, L. Weiss, M. Hasselmann, M. Pinget, R. Kessler, L. Kessler, Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Horm. Metab. Res. 40, 502–506 (2008)PubMedCrossRef
26.
Zurück zum Zitat S.V. Madhu, S.K. Muduli, R. Avasthi, Abnormal glycemic profiles by CGMS in obese first-degree relatives of type 2 diabetes mellitus patients. Diabetes Technol. Ther. 15, 461–465 (2013)PubMedCrossRef S.V. Madhu, S.K. Muduli, R. Avasthi, Abnormal glycemic profiles by CGMS in obese first-degree relatives of type 2 diabetes mellitus patients. Diabetes Technol. Ther. 15, 461–465 (2013)PubMedCrossRef
27.
Zurück zum Zitat R. Borg, J.C. Kuenen, B. Carstensen, H. Zheng, D.M. Nathan, R.J. Heine, J. Nerup, K. Borch-Johnsen, D.R. Witte, ADAG Study Group, Real-life glycaemic profiles in non-diabetic individuals with low fasting glucose and normal HbA1c: the A1C-derived average glucose (ADAG) study. Diabetologia 53, 1608–1611 (2010)PubMedCentralPubMedCrossRef R. Borg, J.C. Kuenen, B. Carstensen, H. Zheng, D.M. Nathan, R.J. Heine, J. Nerup, K. Borch-Johnsen, D.R. Witte, ADAG Study Group, Real-life glycaemic profiles in non-diabetic individuals with low fasting glucose and normal HbA1c: the A1C-derived average glucose (ADAG) study. Diabetologia 53, 1608–1611 (2010)PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat C. Wang, L. Lv, Y. Yang, D. Chen, G. Liu, L. Chen, Y. Song, L. He, X. Li, H. Tian, W. Jia, X. Ran, Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.) 76, 810–815 (2012)CrossRef C. Wang, L. Lv, Y. Yang, D. Chen, G. Liu, L. Chen, Y. Song, L. He, X. Li, H. Tian, W. Jia, X. Ran, Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.) 76, 810–815 (2012)CrossRef
29.
Zurück zum Zitat A. Lapolla, A. Mosca, D. Fedele, The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr. Metab. Cardiovasc. Dis. 21, 467–475 (2011)PubMedCrossRef A. Lapolla, A. Mosca, D. Fedele, The general use of glycated haemoglobin for the diagnosis of diabetes and other categories of glucose intolerance: still a long way to go. Nutr. Metab. Cardiovasc. Dis. 21, 467–475 (2011)PubMedCrossRef
30.
Zurück zum Zitat A. Sciacqua, R. Maio, S. Miceli, A. Pascale, G. Carullo, N. Grillo, F. Arturi, G. Sesti, F. Perticone, Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. PLoS One 7, e44470 (2012)PubMedCentralPubMedCrossRef A. Sciacqua, R. Maio, S. Miceli, A. Pascale, G. Carullo, N. Grillo, F. Arturi, G. Sesti, F. Perticone, Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. PLoS One 7, e44470 (2012)PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat A. Sciacqua, S. Miceli, G. Carullo, L. Greco, E. Succurro, F. Arturi, G. Sesti, F. Perticone, One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients. Diabetes Care 34, 1406–1411 (2011)PubMedCentralPubMedCrossRef A. Sciacqua, S. Miceli, G. Carullo, L. Greco, E. Succurro, F. Arturi, G. Sesti, F. Perticone, One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients. Diabetes Care 34, 1406–1411 (2011)PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat A. Sciacqua, S. Miceli, L. Greco, F. Arturi, P. Naccarato, D. Mazzaferro, E.J. Tassone, L. Turano, F. Martino, G. Sesti, F. Perticone, One-hour postload plasma glucose levels and diastolic function in hypertensive patients. Diabetes Care 34, 2291–2296 (2011)PubMedCentralPubMedCrossRef A. Sciacqua, S. Miceli, L. Greco, F. Arturi, P. Naccarato, D. Mazzaferro, E.J. Tassone, L. Turano, F. Martino, G. Sesti, F. Perticone, One-hour postload plasma glucose levels and diastolic function in hypertensive patients. Diabetes Care 34, 2291–2296 (2011)PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat N. Taheri, B. Iraj, M. Amini, P. Amini, A. Aminorroaya, Cardiovascular risk factors in relatives of type 2 diabetics with normal glucose tolerance test and elevated one-hour plasma glucose. Endokrynol. Pol. 61, 359–363 (2010)PubMed N. Taheri, B. Iraj, M. Amini, P. Amini, A. Aminorroaya, Cardiovascular risk factors in relatives of type 2 diabetics with normal glucose tolerance test and elevated one-hour plasma glucose. Endokrynol. Pol. 61, 359–363 (2010)PubMed
34.
Zurück zum Zitat K. Torimoto, Y. Okada, H. Mori, Y. Tanaka, Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc. Diabetol. 12, 1 (2013)PubMedCentralPubMedCrossRef K. Torimoto, Y. Okada, H. Mori, Y. Tanaka, Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc. Diabetol. 12, 1 (2013)PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat M. Brownlee, Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001)PubMedCrossRef M. Brownlee, Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001)PubMedCrossRef
36.
Zurück zum Zitat M. Brownlee, The pathophysiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005)PubMedCrossRef M. Brownlee, The pathophysiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005)PubMedCrossRef
37.
Zurück zum Zitat M.A. Marini, E. Succurro, S. Frontoni, S. Mastroianni, F. Arturi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 35, 868–872 (2012)PubMedCentralPubMedCrossRef M.A. Marini, E. Succurro, S. Frontoni, S. Mastroianni, F. Arturi, A. Sciacqua, R. Lauro, M.L. Hribal, F. Perticone, G. Sesti, Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care 35, 868–872 (2012)PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat M. Bergman, Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 43, 504–513 (2013)PubMedCrossRef M. Bergman, Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 43, 504–513 (2013)PubMedCrossRef
39.
Zurück zum Zitat R.E. Pratley, C. Weyer, The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44, 929–945 (2001)PubMedCrossRef R.E. Pratley, C. Weyer, The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44, 929–945 (2001)PubMedCrossRef
40.
Zurück zum Zitat M. Fukushima, H. Suzuki, Y. Seino, Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res. Clin. Pract. 66, S37–S43 (2004)PubMedCrossRef M. Fukushima, H. Suzuki, Y. Seino, Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res. Clin. Pract. 66, S37–S43 (2004)PubMedCrossRef
41.
Zurück zum Zitat S. Del Prato, Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 46, M2–M8 (2003)PubMed S. Del Prato, Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 46, M2–M8 (2003)PubMed
42.
Zurück zum Zitat R.N. Bergman, M. Ader, K. Huecking, G. Van Citters, Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51, S212–S220 (2002)PubMedCrossRef R.N. Bergman, M. Ader, K. Huecking, G. Van Citters, Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51, S212–S220 (2002)PubMedCrossRef
43.
Zurück zum Zitat K.D. Kohnert, P. Augstein, E. Zander, P. Heinke, K. Peterson, E.J. Freyse, R. Hovorka, E. Salzsieder, Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 32, 1058–1062 (2009)PubMedCentralPubMedCrossRef K.D. Kohnert, P. Augstein, E. Zander, P. Heinke, K. Peterson, E.J. Freyse, R. Hovorka, E. Salzsieder, Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 32, 1058–1062 (2009)PubMedCentralPubMedCrossRef
Metadaten
Titel
Glycemic variability in normal glucose regulation subjects with elevated 1-h postload plasma glucose levels
verfasst von
Jian-bin Su
Tong Chen
Feng Xu
Xue-qin Wang
Jin-feng Chen
Gang Wu
Yan Jin
Xiao-hua Wang
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0047-3

Weitere Artikel der Ausgabe 2/2014

Endocrine 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.